Cargando…
2299. Longitudinal Serological Surveillance of SARS-CoV-2 in Children and Adolescents Using Serial At-Home Testing
BACKGROUND: Longitudinal serological surveillance is critical to understand dynamics of SARS-CoV-2 infections in children, a substantial portion of whom are asymptomatic. We describe trends in seroprevalence using at-home testing and evaluate demographic and clinical characteristics associated with...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751902/ http://dx.doi.org/10.1093/ofid/ofac492.137 |
_version_ | 1784850586410156032 |
---|---|
author | Ahmed, Amina DeWitt, Michael E Uschner, Diane Lagarde, William H Friedman-Klabanoff, DeAnna J Santos, Roberto P Gibbs, Michael A Tapp, Hazel Dantuluri, Keerti L |
author_facet | Ahmed, Amina DeWitt, Michael E Uschner, Diane Lagarde, William H Friedman-Klabanoff, DeAnna J Santos, Roberto P Gibbs, Michael A Tapp, Hazel Dantuluri, Keerti L |
author_sort | Ahmed, Amina |
collection | PubMed |
description | BACKGROUND: Longitudinal serological surveillance is critical to understand dynamics of SARS-CoV-2 infections in children, a substantial portion of whom are asymptomatic. We describe trends in seroprevalence using at-home testing and evaluate demographic and clinical characteristics associated with seroconversion. METHODS: Children 2–17 years old enrolled at 3 North Carolina sites (Figure 1) were followed April 2- December 31, 2021. Daily electronic surveys solicited symptoms and vaccination status. Four fingerprick lateral flow immunoassay tests were shipped to participants to be completed monthly; sensitivity and specificity were 84.5% and 99.0%, respectively. We defined an infection window as 30 days before a positive antibody test (IgG), excluding results after any vaccine. Asymptomatic was defined as absence of “new” symptoms in the window; “new” was defined as not occurring the 14 days preceding the first observation of the symptom in the window. Univariate logistic regression was used to compare participants with and without infection-induced antibodies. For estimated seroprevalence, we used Bayesian inference accounting for sensitivity and specificity, modeling IgG positives from a binomial distribution. [Figure: see text] RESULTS: Of 1,501 participants, 9.1% developed infection-induced antibody (Table 1). Blacks were more likely to seroconvert (OR 1.95 [95% CI 1.05–3.45]) as were those in a 5-or-more person household (OR 4.25 [CI 1.47–12.1]). Cumulative seroprevalence of SARS-CoV-2 increased from 12.7% in May to 32.4% in October (Figure 2); 61% of those seropositive were asymptomatic (Table 2). Adolescents had the highest seroconversion rates and were significantly more likely than 2–4-year olds to be asymptomatic. [Figure: see text] [Figure: see text] Bayesian seroprevalence estimates accounting for assay sensitivity and specificity. Error bars represent 95% credible intervals. [Figure: see text] CONCLUSION: Prior SARS-CoV-2 seroprevalence data in children are limited by cross sectional design and use of convenience samples. With serial testing, we demonstrate rising SARS-CoV-2 seroprevalence, with highest rates of seroconversion in adolescents. Although prior findings suggest that asymptomatic infections occur most frequently in young children, we found a high proportion among adolescents. Our findings underscore the importance of serosurveillance to optimize public health efforts aimed at children and adolescents. DISCLOSURES: Roberto P. Santos, MD, MSCS, American Board of Pediatrics - Sub-Board Infectious Diseases: Honoraria|Eli Lilly and Company: Grant/Research Support|Eli Lilly and Company: Eli Lilly and Company awarded to the University of Mississippi Medical Center with Roberto P. Santos as the Site PI|Health Resources and Services Administration (HRSA): Grant/Research Support|Health Resources and Services Administration (HRSA): Program Director & Principal Investigator|Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ): Grant/Research Support|Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ): Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ) awarded to the University of Mississippi Medical Center with Roberto P. Santos as the Site|Merck Sharp & Dohme (MSD): Grant/Research Support|Merck Sharp & Dohme (MSD): Merck Sharp & Dohme (MSD) awarded to the University of Mississippi Medical Center with Roberto P. Santos as the Site PI. |
format | Online Article Text |
id | pubmed-9751902 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-97519022022-12-16 2299. Longitudinal Serological Surveillance of SARS-CoV-2 in Children and Adolescents Using Serial At-Home Testing Ahmed, Amina DeWitt, Michael E Uschner, Diane Lagarde, William H Friedman-Klabanoff, DeAnna J Santos, Roberto P Gibbs, Michael A Tapp, Hazel Dantuluri, Keerti L Open Forum Infect Dis Abstracts BACKGROUND: Longitudinal serological surveillance is critical to understand dynamics of SARS-CoV-2 infections in children, a substantial portion of whom are asymptomatic. We describe trends in seroprevalence using at-home testing and evaluate demographic and clinical characteristics associated with seroconversion. METHODS: Children 2–17 years old enrolled at 3 North Carolina sites (Figure 1) were followed April 2- December 31, 2021. Daily electronic surveys solicited symptoms and vaccination status. Four fingerprick lateral flow immunoassay tests were shipped to participants to be completed monthly; sensitivity and specificity were 84.5% and 99.0%, respectively. We defined an infection window as 30 days before a positive antibody test (IgG), excluding results after any vaccine. Asymptomatic was defined as absence of “new” symptoms in the window; “new” was defined as not occurring the 14 days preceding the first observation of the symptom in the window. Univariate logistic regression was used to compare participants with and without infection-induced antibodies. For estimated seroprevalence, we used Bayesian inference accounting for sensitivity and specificity, modeling IgG positives from a binomial distribution. [Figure: see text] RESULTS: Of 1,501 participants, 9.1% developed infection-induced antibody (Table 1). Blacks were more likely to seroconvert (OR 1.95 [95% CI 1.05–3.45]) as were those in a 5-or-more person household (OR 4.25 [CI 1.47–12.1]). Cumulative seroprevalence of SARS-CoV-2 increased from 12.7% in May to 32.4% in October (Figure 2); 61% of those seropositive were asymptomatic (Table 2). Adolescents had the highest seroconversion rates and were significantly more likely than 2–4-year olds to be asymptomatic. [Figure: see text] [Figure: see text] Bayesian seroprevalence estimates accounting for assay sensitivity and specificity. Error bars represent 95% credible intervals. [Figure: see text] CONCLUSION: Prior SARS-CoV-2 seroprevalence data in children are limited by cross sectional design and use of convenience samples. With serial testing, we demonstrate rising SARS-CoV-2 seroprevalence, with highest rates of seroconversion in adolescents. Although prior findings suggest that asymptomatic infections occur most frequently in young children, we found a high proportion among adolescents. Our findings underscore the importance of serosurveillance to optimize public health efforts aimed at children and adolescents. DISCLOSURES: Roberto P. Santos, MD, MSCS, American Board of Pediatrics - Sub-Board Infectious Diseases: Honoraria|Eli Lilly and Company: Grant/Research Support|Eli Lilly and Company: Eli Lilly and Company awarded to the University of Mississippi Medical Center with Roberto P. Santos as the Site PI|Health Resources and Services Administration (HRSA): Grant/Research Support|Health Resources and Services Administration (HRSA): Program Director & Principal Investigator|Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ): Grant/Research Support|Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ): Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ) awarded to the University of Mississippi Medical Center with Roberto P. Santos as the Site|Merck Sharp & Dohme (MSD): Grant/Research Support|Merck Sharp & Dohme (MSD): Merck Sharp & Dohme (MSD) awarded to the University of Mississippi Medical Center with Roberto P. Santos as the Site PI. Oxford University Press 2022-12-15 /pmc/articles/PMC9751902/ http://dx.doi.org/10.1093/ofid/ofac492.137 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Abstracts Ahmed, Amina DeWitt, Michael E Uschner, Diane Lagarde, William H Friedman-Klabanoff, DeAnna J Santos, Roberto P Gibbs, Michael A Tapp, Hazel Dantuluri, Keerti L 2299. Longitudinal Serological Surveillance of SARS-CoV-2 in Children and Adolescents Using Serial At-Home Testing |
title | 2299. Longitudinal Serological Surveillance of SARS-CoV-2 in Children and Adolescents Using Serial At-Home Testing |
title_full | 2299. Longitudinal Serological Surveillance of SARS-CoV-2 in Children and Adolescents Using Serial At-Home Testing |
title_fullStr | 2299. Longitudinal Serological Surveillance of SARS-CoV-2 in Children and Adolescents Using Serial At-Home Testing |
title_full_unstemmed | 2299. Longitudinal Serological Surveillance of SARS-CoV-2 in Children and Adolescents Using Serial At-Home Testing |
title_short | 2299. Longitudinal Serological Surveillance of SARS-CoV-2 in Children and Adolescents Using Serial At-Home Testing |
title_sort | 2299. longitudinal serological surveillance of sars-cov-2 in children and adolescents using serial at-home testing |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751902/ http://dx.doi.org/10.1093/ofid/ofac492.137 |
work_keys_str_mv | AT ahmedamina 2299longitudinalserologicalsurveillanceofsarscov2inchildrenandadolescentsusingserialathometesting AT dewittmichaele 2299longitudinalserologicalsurveillanceofsarscov2inchildrenandadolescentsusingserialathometesting AT uschnerdiane 2299longitudinalserologicalsurveillanceofsarscov2inchildrenandadolescentsusingserialathometesting AT lagardewilliamh 2299longitudinalserologicalsurveillanceofsarscov2inchildrenandadolescentsusingserialathometesting AT friedmanklabanoffdeannaj 2299longitudinalserologicalsurveillanceofsarscov2inchildrenandadolescentsusingserialathometesting AT santosrobertop 2299longitudinalserologicalsurveillanceofsarscov2inchildrenandadolescentsusingserialathometesting AT gibbsmichaela 2299longitudinalserologicalsurveillanceofsarscov2inchildrenandadolescentsusingserialathometesting AT tapphazel 2299longitudinalserologicalsurveillanceofsarscov2inchildrenandadolescentsusingserialathometesting AT dantulurikeertil 2299longitudinalserologicalsurveillanceofsarscov2inchildrenandadolescentsusingserialathometesting |